SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Transgene S.A. (TRGNF) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 23/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — TRGNF
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio1,053.86
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.26
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.44 |
$2.35M |
$-25.21M |
-1074.5% |
| 2017 |
$-0.51 |
$2.1M |
$-32.27M |
-1537.6% |
| 2018 |
$0.13 |
$1.34M |
$8.03M |
601.2% |
| 2019 |
$-0.23 |
$13.3M |
$-18.8M |
-141.4% |
| 2020 |
$-0.22 |
$2.98M |
$-18.45M |
-618.9% |
| 2021 |
$-0.22 |
$9.99M |
$-20M |
-200.2% |
| 2022 |
$-0.33 |
$3.13M |
$-32.81M |
-1049.6% |
| 2023 |
$-0.22 |
$7.9M |
$-22.33M |
-282.6% |
| 2024 |
$-0.34 |
$307K |
$-33.97M |
-11065.5% |
| 2025 |
$-0.26 |
$136.95K |
$-37.51M |
-27390.1% |
